Direct Transition Without Overlap or Washout
You can switch directly from metoprolol succinate 25 mg to diltiazem ER 120 mg without a washout period or dose overlap. Simply stop the metoprolol and start the diltiazem the next day.
Rationale for Direct Switch
Both metoprolol and diltiazem are used for rate control in conditions like atrial fibrillation and hypertension, and guidelines support their use as alternatives to each other 1, 2, 3. The dose of metoprolol succinate 25 mg is relatively low (maintenance doses range 25-200 mg twice daily per guidelines 1), and diltiazem ER 120 mg represents a standard starting dose (maintenance range 120-360 mg daily 1, 4, 5).
The key consideration is that both drugs slow AV conduction and reduce heart rate through different mechanisms (beta-blockade vs. calcium channel blockade), so overlapping them significantly increases the risk of excessive bradycardia and heart block 6.
Practical Switching Protocol
- Day 1: Give last dose of metoprolol succinate 25 mg
- Day 2: Start diltiazem ER 120 mg once daily
- Monitor closely for 48-72 hours for:
- Heart rate (target >50-60 bpm at rest)
- Blood pressure (watch for hypotension)
- Symptoms of bradycardia (dizziness, fatigue, syncope)
- Signs of heart block on ECG if available
Critical Monitoring Points
Check baseline parameters before switching:
- Current heart rate and blood pressure
- Presence of any AV block on ECG (first-degree or higher)
- Renal function (both drugs require dose adjustment in renal impairment)
- Left ventricular function (diltiazem should be avoided in decompensated heart failure or severe LV dysfunction 7, 4, 5)
The most important contraindication to watch for is pre-existing AV block greater than first-degree or sick sinus syndrome without a pacemaker 4, 5. Both drugs can worsen conduction abnormalities, but diltiazem poses particular risk in patients with reduced ejection fraction 7.
Drug Interaction Considerations
The FDA label for metoprolol warns that both digitalis glycosides and beta-blockers slow AV conduction, and concomitant use increases bradycardia risk 6. This same principle applies when switching between rate-controlling agents. Research shows that diltiazem can increase metoprolol concentrations when given together 8, which is why you should never overlap these medications.
Evidence for Direct Switching
While no specific guideline addresses the exact transition protocol, the 2024 ACC/AHA/HRS guidelines list both metoprolol and diltiazem as equivalent Class I recommendations for rate control 3. Research comparing these agents shows they have similar efficacy for rate control, though diltiazem may achieve faster rate reduction 9, 10, 11, 12. The 25 mg dose of metoprolol succinate is low enough that abrupt discontinuation poses minimal rebound risk, unlike higher doses where gradual tapering might be considered.
Common Pitfalls to Avoid
- Never overlap both medications - this dramatically increases bradycardia and hypotension risk
- Don't use diltiazem if the patient has heart failure with reduced ejection fraction - it has negative inotropic effects 7, 4, 5
- Avoid in patients with accessory pathways (WPW syndrome) and atrial fibrillation - can accelerate ventricular response 13, 4, 5
- Watch for hypotension more carefully with diltiazem - recent meta-analyses show diltiazem has higher rates of adverse events including hypotension compared to metoprolol 11, 12